托伐普坦治疗慢性心力衰竭伴低氯血症的临床效果

Abstract
Figure/Table
References (18)
Related Citation (15)

Download: PDF (0 KB) HTML (35 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the clinical effect of Tolvaptan in the treatment of chronic heart failure(CHF)with hypochloremia.Methods A total of 60 patients with CHF combined with hypochloremia treated in Heping Hospital Affiliated to Changzhi Medical College from September 2018 to June 2019 were retrospectively selected as research subjects.They were divided into the control group(n=30)and the observation group(n=30)according to the treatment method.Loop diuretic was given to the control group,and Tolvaptan was given to the observation group.The treatment time was one week.The serum chloride,serum sodium,serum potassium,urea nitrogen,serum creatinine,serum hydrogen carbonate(HCO3-),serum albumin,N-terminal pro brain natriuretic peptide(NT-proBNP)before and after treatment in the two groups were compared.The clinical symptom and the rehospitalization rate of cardiovascular disease in half a year after discharge in the two groups were also compared.Results The significant efficiency in the observation group after treatment was higher than that in the control group,with statistically significant difference(P＜0.05).The levels of urea nitrogen,serum creatinine and NT-proBNP in the observation group after treatment were lower than those in the control group,and the serum chloride level in the observation group after treatment was higher than that in the control group,with statistically significant differences(P＜0.05).There were no statistically significant differences in the levels of serum albumin,HCO3-,serum sodium(P＞0.05).There was no statistically significant difference in the rehospitalization rate of cardiovascular disease 6 months of treatment between the two groups(P＞0.05).Conclusion The use of Tolvaptan in patients with CHF and hypochloremia can improve hypochloremia,heart function and renal function in the short term.

Key words： Chronic heart failure Hypochloremia Tolvaptan Loop diuretic

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	YAO Zhang-lu
	DONG Bin

Cite this article:

YAO Zhang-lu,DONG Bin. Clinical effect of Tolvaptan in treatment of chronic heart failure with hypochloremia[J]. 中国当代医药, 2021, 28(25): 76-79.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I25/76

[1]	中华医学会心血管病学分会心力衰竭学组，中国医师协会心力衰竭专业委员会，中华心血管病杂志编辑委员会.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[2]	中国医师协会心力衰竭专业委员会，中华心力衰竭和心肌病杂志编辑委员会.心力衰竭容量管理中国专家建议[J].中华心力衰竭和心肌病杂志（中英文），2018，（1），8-16.
[3]	Ziaeian B，Fonarow GC.Epidemiology and aetiology of heart failure[J].Nat Rev Cardiol，2016，13（6）：368-378.
[4]	Hauptman PJ.Clinical challenge of hyponatremia in heart failure[J].J Hosp Med，2012，7（Suppl 4）：S6-10.
[5]	Grodin JL，Simon J，Hachamovitch R，et al.Prognostic Role of Serum Chloride Levels in Acute Decompensated Heart Failure[J].J Am Coll Cardiol，2015，66（6）：659-666.
[6]	Felker GM，Mentz RJ，Cole RT，et al.Efficacy and Safety of Tolvaptan in Patients Hospitalized With Acute Heart Failure[J].J Am Coll Cardiol，2017，69（11）：1399-406.
[7]	Kazory A，Costanzo MR.The dynamic relationship between serum chloride and cardiorenal syndrome[J].Rev Cardiovasc Med，2020，21（1）：25-29.
[8]	Yancy CW，Jessup M，Bozkurt B，et al.2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure：A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America[J].Circulation.2017，136（6）：e137-e161.
[9]	Hanberg JS，Rao V，Ter Maaten JM，et al.Hypochloremia and diuretic resistance in heart failure：mechanistic insights[J].Circ Heart Fail，2016，9（8）：e003180.
[10]	Rusinaru D，Tribouilloy C，Berry C，et al.Relationship of serum sodium concentration to mortality in a wide spectrum of heart failure patients with preserved and with reduced ejection fraction：an individual patient data metaanalysis（dagger）：meta-analysis global group in chronic heart failure（MAGGIC）[J].Eur J Heart Fail，2012，14（10）：1139-1146.
[11]	Kurtz A.Control of renin synthesis and secretion[J].Am J Hypertens，2012，25（8）：839-847.
[12]	刘洪泽，李广平.低氯血症增加慢性心力衰竭患者住院时间及院内死亡率[J].天津医科大学学报，2017，23（4）：334-336.
[13]	刘洪泽，郭兆增，妥少勇，等.慢性心力衰竭住院患者入院时低氯血症的发生率及相关因素分析[J].中华老年心脑血管病杂志，2019，21（12）：1265-1268.
[14]	刘洪泽，崔丽，曹月娟.低氯血症与心力衰竭的研究进展[J].中华老年心脑血管病杂志，2019，21（9）：995-997.
[15]	卜宪环，董彬.慢性心力衰竭合并低氯血症的临床特点及预后研究[J].当代医学，2020，26（31）：13-16.
[16]	孙明超，李树仁，田焕平.低氯血症与心力衰竭研究进展[J].岭南心血管病杂志，2020，26（6）：725-727.
[17]	Testani JM，Hanberg JS，Arroyo JP，et al.Hypochloremia is strongly and independently associated with mortality in patients with chronic heart failure[J].Eur J Heart Fail，2016，18：660-668.
[18]	Kataoka H.Vasopressin antagonist-like effect of acetazolamide in a heart failure patient：a case report[J].Eur Heart J Case Rep，2018，2（3）：yty076.